Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13174
Sealed predictions
- ARHGAP45 in dopamine neurons, braak-0.44 (p 0.237) → -0.69 (p 0.042)receipt 13182
Swarm cases
receipt 13182: ARHGAP45 in dopamine neurons, braak
- power
- full sample -0.55 (p 0.017, n 18), 95% CI -0.81 to -0.12. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.55 (p 0.019, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.53 (p 0.025, n 18). not the mix.
- skeptic
- leave-one-out range -0.70 to -0.50, sign flips 0; without severely affected donors -0.55 (p 0.017, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.76 (p 2.7e-4, n 18) vs -0.55 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARHGAP45 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ARHGAP45 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.23 p 0.424 (needs p < 1.7e-4)
Receipts
loading the receipts